title: Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo.
abstract: Transitional cell carcinoma (TCC) of the bladder is associated with characterized lesions in dominant and recessive oncogenes. The understanding of the molecular basis of tumorigenesis in these instances makes possible the application of gene therapy strategies for TCC. In this regard, the ability to directly access the epithelium of the genitourinary (GU) tract via the urethra provides a practical means to implement these various gene therapy approaches. We thus explored vector strategies to accomplish direct in vivo transduction of GU epithelium. Initially, three human (HT 1197, HT 1376, T24) and one mouse (MBT-2) TCC cell lines were transduced using a recombinant adenoviral vector expressing the firefly luciferase reporter gene, rAd-CMV-Luc. In these studies, reporter gene expression was found to be significantly elevated above background for all four cell lines. Of note, the TCC cell lines HT 1197 and HT 1376 showed expression levels comparable with the cervical carcinoma cell line HeLa, a cell line previously shown to be highly susceptible to recombinant adenovirus-mediated gene transduction. An in vitro time course for T24 and MBT-2 using rAd-CMV-Luc showed peak expression 1 day after transduction for the T24 line and 3 days after transduction for the MBT-2 line, with detectable levels of expression persisting for at least 7 days. As a next step, human and mouse primary tissue deriving from the GU epithelium were transduced using rAd-CMV-Luc. In this assay, luciferase expression levels significantly above background were observed in both instances.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Comprehensive Cancer Center, University of Alabama, Birmingham 35294, USA.
authors.forename: C
authors.initials: C
authors.lastname: Bass
authors.forename: G
authors.initials: G
authors.lastname: Cabrera
authors.forename: A
authors.initials: A
authors.lastname: Elgavish
authors.forename: B
authors.initials: B
authors.lastname: Robert
authors.forename: G P
authors.initials: GP
authors.lastname: Siegal
authors.forename: S C
authors.initials: SC
authors.lastname: Anderson
authors.forename: D C
authors.initials: DC
authors.lastname: Maneval
authors.forename: D T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D004848:Epithelium / Q000378:metabolism / Q000821:virology; D005260:Female; D017930:Genes, Reporter; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008156:Luciferases / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D017207:Rats, Sprague-Dawley; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis*; D014162:Transfection; D014407:Tumor Cells, Cultured; D001743:Urinary Bladder / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D001616:beta-Galactosidase / Q000096:biosynthesis / Q000235:genetics
chemical_list: D011993:Recombinant Fusion Proteins; D008156:Luciferases; D001616:beta-Galactosidase